Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Providence Health System

Neither a doctor nor a teaching hospital

Research payments

$332,598

35 payments

Through program year 2025, Providence Health System is reported as receiving $332,598 in research payments, across 35 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $204,765 15
2024 Research $41,048 10
2023 Research $1,894 2
2022 Research $20,179 3
2021 Research $31,283 3
2020 Research $9,755 1
2019 Research $23,674 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Genmab U.S., Inc. $165,463 10 payments
  2. Eli Lilly and Company $52,593 9 payments
  3. AbbVie, Inc. $40,419 8 payments
  4. Daiichi Sankyo Inc. $35,000 1 payment
  5. Genentech, Inc. $18,023 1 payment
  6. Novocure GmbH $14,123 1 payment
  7. Myriad Genetic Laboratories, Inc. $3,729 3 payments
  8. Merck Sharp & Dohme Corporation $1,875 1 payment
  9. Hoffmann-La Roche Limited $1,373 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer $165,463 10 payments
  2. A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer $50,699 7 payments
  3. Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) $36,806 4 payments
  4. Ds8201-772 $35,000 1 payment
  5. T Dm1 Atezolizumab in High Risk Her2 Patients With Residual Disease $18,023 1 payment
  6. EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma $14,123 1 payment
  7. Md01 $3,729 3 payments
  8. Study of Ibrutinib and Rituximab in Treatment Naive Follicular Lymphoma $3,280 3 payments
  9. A Randomized Open-Label Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk Node Positive Early Stage Hormone Receptor Positive Human Epidermal Receptor 2 Negative Breast Cancer $1,894 2 payments
  10. A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC $1,875 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record